Russia's Health Ministry has approved the first and second stages of clinical trials of the Betuvax-CoV-2 COVID-19 vaccine, according to the clinical trials authorization register’s data, APA reports citing TASS.
As for the latest data, the research permit for Betuvax-CoV-2, issued on September 27, 2021, remains valid until August 31, 2022. The first and second phases of trials will be carried out on 170 patients.
It is noted that the jab was produced in the form of a suspension for intramuscular administration. The clinical trials are likely to be conducted in Russia’s second-largest city St. Petersburg as well as in Perm.
The Betuvax-CoV-2 is a split recombinant vaccine based on spherical particles with the coronavirus surface antigen (protein). The developers say the jab can be used to inoculate those at risk and can be used for revaccination. The development work on the vaccine began in the summer of 2020.
The clinical trials are expected to involve 116 volunteers aged from 18 to 60 without chronic diseases.